What Is My Dental Practice Worth? Why the Answer Depends Entirely on Who's Buying

If you ask a dental broker what your practice is worth, you will get a number. If you ask a private equity-backed DSO’s underwriting team the same question about the same practice on the same day, you will get a different number — potentially a dramatically different one.

Neither answer is wrong. They are the outputs of two entirely different valuation models, applied by two entirely different types of buyers, with two entirely different definitions of what your practice actually is.

This distinction — individual buyer versus institutional buyer — is the most important concept in dental practice valuation that most founders never understand until they are already in a transaction. And the gap between the two numbers is not cosmetic. On a mid-size group practice, the spread between what an individual dentist will pay and what a PE-backed DSO will pay for the same asset can exceed $1 million in either direction depending on how the practice is built.

What your practice is worth is not a single number. It is a range defined by your buyer type — and the preparation you do in the years before a transaction is either expanding or compressing that range right now.

This post explains how each valuation model works, what drives the number in each case, and where PDA sits in the process — because we are not a valuation firm and do not provide appraisals. What we do is the forensic work that makes whichever valuation your broker produces actually defensible when a buyer’s diligence team arrives.

The two buyer types — and why they value practices differently

The individual buyer: a dentist purchasing a practice

An individual dentist buying a dental practice is acquiring a clinical business they intend to operate personally. Their valuation framework reflects that reality. They are not buying a financial instrument. They are buying a job, a patient base, a facility, and a team — and they are paying for it primarily out of debt financing, usually an SBA loan.

This buyer type uses Seller’s Discretionary Earnings (SDE) as the primary valuation metric. SDE is the practice’s net income plus the owner’s total compensation, benefits, and personal expenses run through the practice — essentially, “what does this practice pay its owner if the new owner steps in and runs it themselves?”

Individual buyers apply a multiple to SDE typically ranging from 1.8x to 2.5x, with the spread driven by a handful of practice-specific factors: owner dependency (if the selling dentist produces 80%+ of total revenue, the buyer is purchasing a patient base personally attached to a departing clinician — high-risk, low-end multiple), hygiene production (a strong hygiene department producing 28–35% of total practice revenue signals recurring revenue that continues regardless of which dentist is in the chair), active patient base size and recency, location and facility condition, and transition structure.

On a practice generating $1.5 million in collections with $450,000 in SDE, an individual buyer might pay $810,000 to $1,125,000. The valuation is relatively straightforward, the financing is standardized, and the due diligence process — while thorough — is conducted by a dental-specific CPA and attorney rather than a forensic analytics team.

This is the traditional dental transition model. It still represents the majority of dental practice sales by volume. And for solo or small practices where the founding dentist is the primary producer and the practice is not built for institutional infrastructure, it is the appropriate and realistic exit path.

The institutional buyer: a PE-backed DSO or dental group

A private equity-backed DSO acquiring your practice is not buying a job. They are buying a financial asset to add to an investment portfolio. Their valuation framework reflects that reality entirely.

This buyer type uses EBITDA — Earnings Before Interest, Taxes, Depreciation, and Amortization — as the primary valuation metric. Specifically, they use adjusted EBITDA: the practice’s earnings normalized to remove owner-specific expenses, one-time items, and related-party transactions, then recalculated to reflect what the practice will earn under institutional ownership.

Institutional buyers apply a multiple to adjusted EBITDA that falls into two distinct tiers:

Platform assets — practices with $3M–$5M+ in normalized EBITDA, single integrated PMS across all locations, centralized revenue cycle management, and a management structure decoupled from the founding clinician — command 9x to 13x multiples.

Add-on assets — single or multi-site practices with strong EBITDA but lacking enterprise-grade infrastructure — command 5x to 8x multiples.

On the same practice generating $1.5 million in collections but now with $300,000 in adjusted EBITDA at a 5x add-on multiple, an institutional buyer pays $1,500,000. At 7x, $2,100,000. The math looks better than the individual buyer scenario — and for many practices it is. But the adjusted EBITDA figure is where the complexity lives. Because the adjustment process is not a friendly negotiation. It is a forensic audit.

What drives the number in each model

For individual buyer valuation

The SDE multiple expands or contracts based primarily on operational transferability — how cleanly the practice’s revenue will transfer to a new owner-operator. The questions an individual buyer and their advisor are asking: Is the patient base loyal to the practice or to the departing dentist personally? Is the team stable and experienced enough to support a transition? Are the lease terms favorable and assignable? Is the equipment current enough that the buyer won’t face immediate capital outlays? Is the hygiene department producing recurring revenue that doesn’t depend on the selling doctor?

A practice that scores well on these factors sits at the top of the SDE multiple range. A practice where the owner produces 90% of revenue, has no associate, and has patient relationships built entirely on personal trust sits at the bottom — or doesn’t attract individual buyers at all.

For institutional buyer valuation

The EBITDA multiple expands or contracts based primarily on EBITDA quality — not just the size of the earnings, but the degree to which those earnings are real, sustainable, and defensible under forensic scrutiny.

This is where the two valuation worlds diverge most sharply. An individual buyer’s CPA reviews your tax returns and P&L. An institutional buyer’s Quality of Earnings team extracts five years of raw PMS data and benchmarks every procedure code against national compliance standards. They are not asking “what did you earn?” They are asking “what will you earn after we strip out everything that doesn’t survive institutional compliance?” The compliance and QoE defense architecture is where this battle is fought.

The specific factors that drive the institutional multiple: normalized EBITDA margin of 19%+ with a demonstrable 36-month upward trend positions for premium consideration. CDT code compliance — procedure utilization rates that deviate from Cotiviti benchmark standards are removed from the EBITDA baseline before the multiple is applied. At 9x, $100,000 in identified non-compliant revenue is $900,000 in enterprise value that doesn’t exist. Provider dependency — no single provider representing more than 35% of collected production for platform classification. Platform versus add-on infrastructure — the 3x to 5x spread between these tiers is the most financially consequential underwriting decision in the process. And the five-year behavioral history — not just the trailing three-year P&L but the full five-year PMS record. This is the exact underwriting process DSOs apply when evaluating acquisitions.

Where PDA sits — and where it doesn’t

This is where we need to be precise about what Precision Dental Analytics is and is not.

We are not a valuation firm. We do not provide practice appraisals. We do not produce the number your broker will present to buyers. For actual practice valuation — the formal appraisal that establishes your asking price and supports your LOI negotiations — you need a dental-specific broker or M&A advisor who knows your market, your buyer pool, and current transaction multiples. That is their expertise and their lane.

What we do is the forensic work that makes that valuation defensible.

Here is the practical distinction. Your broker produces a valuation of $4.2 million based on your trailing EBITDA and a negotiated 8x multiple. That number is accurate based on what your P&L reports. The question PDA answers is: how much of that $4.2 million survives the buyer’s forensic audit?

If your D2950 utilization rate is 78% against a Cotiviti benchmark of 40%, and that anomaly represents $95,000 in non-compliant revenue, your buyer’s QoE team will identify it and remove it from the EBITDA baseline before applying the multiple. That is not a negotiation. That is arithmetic. At 8x, $95,000 in removed EBITDA is $760,000 in enterprise value that evaporated between your broker’s number and the closing table.

PDA operates in two distinct lanes for the strategic seller:

Lane 1 — Increase EBITDA: Identifying the operational and clinical gaps that are suppressing your defensible earnings. The hygiene department running at 23% of total production when institutional benchmark is 28–35%. The collections rate at 94% when 98%+ is achievable with billing discipline. The fee schedule structure leaving revenue on the table. These are not forensic problems — they are operational opportunities. Closing them before a transaction increases the EBITDA your broker has to work with.

Lane 2 — De-risk EBITDA: Identifying the forensic vulnerabilities that will compress the EBITDA your broker presents. The CDT coding patterns that a buyer’s compliance team will flag. The aged patient credits that trigger escheatment liability. The provider classification structures that produce successor liability holdbacks. The behavioral signals in your five-year PMS history that a buyer’s analyst will surface and use to justify a re-trade or holdback charge. Eliminating these before a buyer’s team finds them is the difference between your broker’s number and what actually lands at the closing table. This is the core of pre-LOI financial forensics.

We work in the years before you engage a broker — specifically the 3 to 5 years before an institutional conversation — to ensure that by the time a valuation is formally produced, the EBITDA underlying it is both maximized and defensible. The broker produces the number. We make the number real.

Which path is right for your practice

The honest answer is that the right exit path depends on your practice’s current profile and your timeline — and that most practices sit somewhere between the two buyer types depending on how they build in the years before a transaction.

The individual buyer path makes sense if you are a solo or small group operator with collections under $1.5M, your production is primarily owner-dependent and you are not planning to build an associate structure, your timeline is 1–3 years and you do not have the runway to build institutional infrastructure, or your priority is a clean transition that preserves your patient relationships and team culture.

The institutional buyer path makes sense if you are running or building a multi-site operation with collections above $2M, you have or are building an associate structure that reduces founder dependency, your timeline is 3–7 years and you have the runway to build institutional-grade infrastructure, or your EBITDA is or can be normalized to $500K+ under institutional methodology.

The practices that command the highest institutional multiples are not necessarily the ones with the highest revenue. They are the ones whose EBITDA is largest, cleanest, most defensible, and best documented — built over years against the standards a DSO’s underwriting team will apply. The 5-Year Exit Architecture is the blueprint for building that asset deliberately.

The valuation your broker produces is a function of what your practice is today. The valuation your practice is capable of generating is a function of what you build between now and the transaction.

The one number that matters most — and what actually determines it

Regardless of buyer type, the single most important factor in your practice’s exit value is not your revenue. It is not your location. It is not your patient count or your equipment or your specialty mix.

It is the relationship between your reported earnings and your defensible earnings.

For an individual buyer, defensible earnings means revenue that will transfer to a new owner-operator without material decline. For an institutional buyer, defensible earnings means revenue that will survive a forensic QoE audit and an algorithmic CDT compliance review without adjustment.

Both buyers are asking the same fundamental question in different languages: is this practice worth what the seller says it’s worth?

The practices that answer that question convincingly — that walk into a transaction with earnings that hold up under scrutiny — are the ones that exit at their stated enterprise value, with minimal holdback exposure, and actual liquidity that matches the number their broker negotiated.

That does not happen by accident. And it does not happen in the 12 months before a sale.

It happens in the years before a broker is ever engaged, when the decisions being made inside the practice are being made with the forensic outcome in mind. Run your free EBITDA Leakage diagnostic →